San Diego, CA. DTx Pharma, an RNA medicines company breaking open new therapeutic areas for oligonucleotide therapeutics, today announced that it will attend the 2018 BIO International Partnering Convention in Boston, MA from June 4-7, 2018.
“The single biggest obstacle limiting the expansion of oligonucleotide therapeutics as a class is delivery,” said Arthur Suckow, Ph.D, CEO/CSO of DTx. “DTx Pharma has developed proprietary technology that has achieved a major breakthrough, and that has, and will continue to break open open new therapeutic areas for this class of medicines. We look forward to meeting with potential partners as we seek to move candidates into early clinical development.
Contact Us Here